Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment

BJU International

Volumn 107, Issue 4, 2011, Pages 540-546

  Kakiashvili, David M ^a   Van Rhijn, Bas W G ^a   Trottier, Greg ^a   Jewett, Michael A S ^a   Fleshner, Neil E ^a   Finelli, Antonio ^a   Azuero, Julian ^a   Bangma, Chris H ^a   Vajpeyi, Rati ^a   Alkhateeb, Sultan ^a   Hanna, Sally ^a   Kostynsky, Alex ^a   Kuk, Cynthia ^a   Van Der Kwast, Theodorus H ^b   Zlotta, Alexandre R ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bacille Calmette Gu rin (BCG); bladder cancer; disease progression; high grade; recurrence; T1

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 78649655000     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09572.x     Document Type: Article

References (46)

1. Brake M, Loertzer H, Horsch R, Keller H,. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697-701
2. Soloway MS, Sofer M, Vaidya A,. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-83
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
4. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE,. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100; discussion
5. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001
6. Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B,. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002; 41: 635-41; discussion 42
7. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-5; discussion 75- 7
8. Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999; 161: 792-8
9. Hautmann RE, Simon J,. Ileal neobladder and local recurrence of bladder cancer: patterns of failure and impact on function in men. J Urol 1999; 162: 1963-6
10. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
11. Cookson MS, Sarosdy MF,. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992; 148: 797-801
12. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN,. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227-31
13. Sylvester RJ, van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
14. Eure GR, Cundiff MR, Schellhammer PF,. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J Urol 1992; 147: 376-9
15. Pfister C, Landé P, Hervé JM, Barré P, Barbagelatta M, Camey M, Botto H,. T1 G3 bladder tumors: the respective role of BCG and cystectomy. Prog Urol 1995; 5: 231-7
16. Hurle R, Losa A, Manzetti A, Lembo A,. Intravesical bacilli Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258-63
17. Serretta V, Piazza S, Pavone C, Piazza B, Pavone-Macaluso M,. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Urology 1996; 47: 647-51
18. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H,. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998; 34: 67-72
19. Baniel J, Grauss D, Engelstein D, Sella A,. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785-9
20. Gohji K, Nomi M, Okamoto M, Takenaka A, Hara I, Okada H, Arakawa S, Fujii A, Kamidono S,. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308-13
21. Brake M, Loertzer H, Horsch R, Keller H,. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697-701
22. Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guillé F, Lobel B,. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002; 41: 635-41
23. Griffiths TR, Charlton M, Neal DE, Powell PH,. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 167: 2408-12
24. Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M,. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder; recurrence, progression and survival in a study of 57 patients. J Urol 2003; 169: 2110-2
25. Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, Li ML,. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol 2004; 34: 202-5
26. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE,. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004; 172: 70-5
27. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M,. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008; 53: 146-52
28. Siref LE, Zincke H,. Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy? Urology 1988; 31: 309-11
29. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, Garbeglio A,. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45-50
30. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF,. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994; 151: 31-5
31. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG,. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995; 76: 833-9
32. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG,. Radical cystectomy in the treatment of invasive bladder cancer: log-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
33. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE,. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-6
34. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M,. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008; 53: 146-52
35. Emiliozzi P, Pansadoro A, Pansadoro V,. The optimal management of T1G3 bladder cancer. BJU Int 2008; 102: 1265-73
36. Herr HW, Donat SM,. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97: 1194-8
37. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66: 108-25
38. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA,. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45: 292-6
39. Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H,. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48: 53-9; discussion 9
40. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR,. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7
41. Bohle A, Bock PR,. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63: 682-6; discussion 6- 7
42. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9
43. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV,. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44: 429-34 (Pubitemid 37185667)
44. Herr HW,. Is maintenance Bacillus Calmette-Guerin really necessary? Eur Urol 2008; 54: 971-3
45. Divrik RT, Yildirim U, Zorlu F, Ozen H,. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 1641-4
46. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W,. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004; 45: 539-46; discussion 46